Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earning In Brief

This article was originally published in The Tan Sheet

Executive Summary

Hi-Tech Pharmacal seeks OTC acquisitions: The pharmaceutical firm plans to bolster its current line of diabetic consumer health products with additional brand acquisitions. The OTC market is "a critical area for future growth and we are continuing to seek acquisitions to build our OTC business," said Hi-Tech Pharmacal CEO David Seltzer March 11. The Amityville, N.Y., company purchased the Mag-Ox magnesium supplement line in early March (1"The Tan Sheet" March 8, 2010, In Brief). For the November-January period, Hi-Tech grew sales in its Health Care Products division, including OTCs, 11.5 percent to $2.9 million, while overall net sales jumped 32 percent to $38.8 million

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS103926

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel